FarrowSure GOLD BThis page contains information on FarrowSure GOLD B for veterinary use.
The information provided typically includes the following:
- FarrowSure GOLD B Indications
- Warnings and cautions for FarrowSure GOLD B
- Direction and dosage information for FarrowSure GOLD B
FarrowSure GOLD BThis treatment applies to the following species:
Erysipelothrix Rhusiopathiae-Leptospira Bratislava-Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin
For use in swine only
This product has been shown to be effective for the vaccination of healthy, breeding swine against reproductive failure caused by porcine parvovirus and disease caused by Erysipelothrix rhusiopathiae, Leptospira bratislava, L. canicola, L. grippotyphosa, L. hardjo, L. icterohaemorrhagiae, and L. pomona. A duration of immunity of at least 18 weeks has been demonstrated against E. rhusiopathiae. Duration of immunity of the remaining fractions has not been established. For more information regarding efficacy and safety data, go to productdata.aphis.usda.gov.
FarrowSure GOLD B is a liquid preparation of porcine parvovirus grown on an established porcine cell line, a serum-free, clarified E. rhusiopathiae culture, and whole cell cultures of the 6 Leptospira serovars identified above. The antigens have been chemically inactivated and adjuvanted with 2 adjuvants, including Amphigen®, to enhance the immune response.
DISEASE DESCRIPTION: PPV and Leptospira are common agents of reproductive loss in swine. While infection with either of these pathogens may produce subclinical disease, infection with PPV during pregnancy may result in fetal resorption, fetal mummification and stillbirths. Infection by Leptospira during the second half of pregnancy may cause abortions and stillbirths; late-term abortions are the most important economic effect of leptospirosis. Leptospirosis caused by any of the serovars represented here cannot be clinically differentiated. Abortions may also occur in sows infected with E. rhusiopathiae during pregnancy.
Directions For Use
General Directions: Shake well. Aseptically administer 2 mL intramuscularly.
Primary Vaccination: Healthy swine should receive 2 doses 3-5 weeks apart with the second dose administered 2-4 weeks prior to breeding. Healthy gilts, however, should receive the second dose as near as possible to 14 days prior to breeding.
For advice on revaccination, consult a veterinarian or the manufacturer.
Good animal husbandry and herd health management practices should be employed.
Store at 2°-8°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze.
Use entire contents when first opened.
Sterilized syringes and needles should be used to administer this vaccine.
Do not vaccinate within 21 days before slaughter.
Transient injection site swelling and/or inappetance may occur following vaccination.
This product has not been tested in pregnant animals.
Contains gentamicin and thimerosal as preservatives.
As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.
Do not mix with other products.
In case of human exposure, contact a physician.
Technical inquiries should be directed to Zoetis Inc. Veterinary Services, (888) 963-8471.
This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished
or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions. For veterinary use only
VLN 190/PCN 4BC5.22
Zoetis Inc., Kalamazoo, MI 49007, USA
333 PORTAGE STREET, KALAMAZOO, MI, 49007
Copyright © 2023 Animalytix LLC. Updated: 2023-05-30